Genomic profiling can identify actionable alterations

We now know that cancer is a disease of the genome.¹ Studies indicate that 30% to 49%
of patients who undergo tumor genomic profiling may have an actionable Actionable means that the alteration is associated with an approved or investigational therapy. alteration.^2,3

30% to 49% of patients who undergo tumor genomic profiling may have an actionable alteration^2,3

LEARN MORE ABOUT TESTING FOR NTRK GENE FUSIONS

References: 1. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846. doi:10.1038/ncomms5846. 2. Boland GM, Piha-Paul SA, Subbiah V, et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015;6(24):20099-20110. 3. Massard C, Michiels S, Ferte C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586-595. 4. Harris MH, DuBois SG, Glade Bender JL, et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the individualized cancer therapy (iCat) study. JAMA Oncol. 2016;2(5):608-615. 5. Parsons DW, Roy A, Yang Y, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2(5):616-624.

Share this page

GENOMIC PROFILING

Genomic profiling can identify actionable alterations

30% to 49% of patients who undergo tumor genomic profiling may have an actionable alteration2,3

30% to 49% of patients who undergo tumor genomic profiling may have an actionable alteration^2,3